Serplulimab Beats Atezolizumab on Overall Survival in US Bridging Study for Extensive-Stage SCLC
Start here
Henlius has released the ASTRIDE abstract ahead of ESMO 2026, a US head-to-head bridging study comparing serplulimab plus chemotherapy against atezolizumab plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer. At a median follow-up of 14.1 months, median overall survival was 12.4 months with serplulimab versus 10.2 months with atezolizumab, and 24-month overall survival rates were 32.2% versus 17.6%. Safety was generally comparable between the two arms, with no new safety signals. The full results will be presented as an oral report at the congress, where HANSIZHUANG has 10 studies accepted in total. The complete data, including further detail on outcomes and adverse events, await the oral presentation.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- zhitongcaijing.comPickHenlius Serplulimab ASTRIDE US Bridging Data to Be Presented Orally at ESMO 2026
Henlius released the ASTRIDE abstract at ESMO 2026. The US head-to-head bridging study will be presented as an oral report on serplulimab versus atezolizumab, both with chemotherapy, as first-line treatment for ES-SCLC. At a median follow-up of 14.1 months, median OS was 12.4 months with serplulimab versus 10.2 months with atezolizumab; 24-month OS rates were 32.2% and 17.6%. Safety was generally comparable between groups with no new safety signals; HANSIZHUANG had 10 studies accepted at the congress.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.